Poolbeg Pharma PLC - Clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need - Appoints a number of former executives of Amryt Pharma PLC to its leadership team. Poolbeg's Chair, Cathal Friel, co-founded both Poolbeg and Amryt Pharma.
David Allmond will join Poolbeg as chief business officer from December 1. Allmond previously held the same role at Amryt. John McEvoy will become senior vice president, chief legal officer, from January 1. McEvoy was global general counsel at Amryt from 2017. Finally, Laura Maher will join as vice president of clinical operations from January 8. Maher joined Amryt in 2018, and as associate director of clinical operations, led the clinical research programmes for multiple products.
Current stock price: 8.03 pence, up 19% on Thursday in London
12-month change: up 8.5%
By Holly Beveridge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Poolbeg Pharma (POLB)